Editorial & Columns CSR by Pharmaceutical Companies and Engagement with SHGs, NGOs & Foundations March 6, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Patent Cliff: Opportunity for Indian Pharmaceutical Companies February 27, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Trump, Tariffs and Trade of Pharmaceuticals from India February 17, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Make in India: PLI for Pharmaceutical Industry February 11, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Union Budget 2025: Impact on Pharmaceutical Sector February 7, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Trump, PEPFAR and Indian Pharmaceutical Industry January 30, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Union Budget 2025: Expectations of Pharmaceutical Industry January 24, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Product Portfolio of Top Indian Pharmaceutical Companies January 15, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns FY24 Review: Attrition and Employee Turnover in Top Indian Pharmaceutical Companies January 2, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Metamorphosis : Jan Aushadhi Scheme to PMBJP December 26, 2024 | Dr. Anil Kumar Angrish | No Comments | More